GBAF Logo
Global Banking & Finance Awards® 2026 Nominations open, free to enter Nominate now →
L

LabTurbo Biotech 7725.TWO · TWD

Health Care · Taipei Exchange · 🇹🇼 Taiwan

Compare

21.00

+0.96%

Close of 9 Nov 2026, in TWD

Search any instrument

Reference data, closing prices and charts across 45,000 companies, plus crypto, commodities and currencies.

About LabTurbo Biotech

Its shares trade on Taipei Exchange under the ticker 7725.TWO. It has been listed since 22 December 2023. In the fiscal year to 31 December 2024, it reported revenue of TWD 73.0m and net income of TWD 13.0m. At that date it held total assets of TWD 1.39bn and shareholders' equity of TWD 1.31bn.

LabTurbo Biotech Corp is a TW-based company operating in Health Care Equipment & Supplies industry. The company is headquartered in Taipei City, Taipei. The company went IPO on 2023-12-22. LabTurbo Biotech Corp is a Taiwan-based company that specializes in fully automated precision medical genetic testing systems and reagent kits, as well as testing services. The firm's products include LabTurbo AIO, a fully automated nucleic acid extraction genetic testing device, nucleic acid extraction reagents, and multi-specimen genetic testing reagents. The firm provides testing services. The firm is also engaged in the operation of sports science centers. The firm sells its products both domestically and internationally.

Figures and description from our data supplier, not checked against the company's own report.

Company facts

Sector
Health Care
Industry
Health Care Equipment & Supplies
Listed since
22 Dec 2023

Environmental, social and governance

Scores out of 100, from our data supplier

ESG
Overall
0
Environment
0
Social
0
Governance
0

SWOT analysis

AI-generated by our data supplier. Not written or checked by our editors.

AI-generated

Strengths

  • LabTurbo AIO fully automated genetic testing device enhances precision medical diagnostics in Taiwan.
  • Nucleic acid extraction reagents support efficient genetic testing processes globally.
  • Multi-specimen genetic testing reagents enable comprehensive health assessments across segments.

Weaknesses

  • Limited domestic market presence in Taipei City for genetic testing services.
  • Dependence on international sales for revenue growth beyond Taiwan.
  • Narrow focus on genetic testing without diversification into other health care segments.

Opportunities

  • Expanding international sales of LabTurbo AIO device in the global health care market.
  • Growing demand for genetic testing reagents in the Asia-Pacific region.
  • Increasing partnerships with sports science centers for integrated health services.

Threats

  • Intense competition from established health care equipment manufacturers in Taiwan.
  • Regulatory changes affecting genetic testing services in international markets.
  • Economic downturns impacting global health care spending on equipment.

Sources and methodology

Data on this tab
Our data supplier
Chart on the Overview
TradingView

Nothing here is investment advice. Prices can be delayed or wrong, so check with the exchange before relying on them. Data for this page. How we cover markets.